Trump announces reforms to accelerate access to psychedelic drug treatments
The Guardian • • general
Key Points:
- President Donald Trump signed an executive order directing the FDA to expedite the review of psychedelic drugs like ibogaine, aiming to speed up access to medical research and treatment.
- The reforms could lead to the reclassification of these drugs, which are currently largely illegal and known to cause hallucinations, after successful clinical trials.
- The US government plans to dedicate $50 million to federal research on ibogaine, a substance noted for its potential to treat PTSD and substance abuse disorders, including opioid addiction.
- Texas is expected to benefit immediately from the order, having already committed $50 million to studying ibogaine, which is derived from a central African shrub root.
- Trump expressed optimism about the impact of these drugs, suggesting they could have significant benefits for the US and other countries if research results are positive.
